Combined, the findings from the PACCE and CAIRO2 trials highlighted that incorporating EGFR inhibitors into the first-line treatment for metastatic colorectal cancer (mCRC) does not improve the clinical outcomes, regardless of the KRAS mutational status, and may potentially diminish the overall effectiveness. This evidence concerns the gene EGFR and metastatic colorectal cancer.